References

Key Findings in AML: An Overview with Eytan M. Stein, MD


[http://www.bloodjournal.org/content/128/22/99?sso-checked=true](http://www.bloodjournal.org/content/128/22/99?sso-checked=true)

Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 with Mark J. Levis, MD, PhD

[http://www.bloodjournal.org/content/132/6/598.long?sso-checked=true](http://www.bloodjournal.org/content/132/6/598.long?sso-checked=true)

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30240-7/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30240-7/fulltext)

Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML with Eytan M. Stein, MD

[http://www.bloodjournal.org/content/early/2017/06/05/blood-2017-04-779405?sso-checked=true](http://www.bloodjournal.org/content/early/2017/06/05/blood-2017-04-779405?sso-checked=true)
Abstracts

**Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 with Mark J. Levis, MD, PhD**


**Strategies for Achieving Durable Responses in Elderly AML Patients with Keith W. Pratz, MD**


**Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML with Eytan M. Stein, MD**


**Emerging Combinations and Therapies in Newly Diagnosed and Relapsed/Refractory AML with Jorge E. Cortes, MD**


©2018 MediCom Worldwide, Inc.

https://learningcenter.ehaweb.org/eha/2018/stockholm/214722/maria.baer.a.phase.1.dose.escalation.study.of.the.idh1m.inhibitor.ft-2102.in.html?f=ce_id=1346*ot_id=19045*media=3